Iterum Therapeutics plc — Director's Dealing 2018

May 30, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2018-05-30

Reporting Person: CANAAN X L.P. (Director, 10% Owner)
Reporting Person: Canaan Partners X LLC (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-30	Ordinary Shares	C	721408	—	Acquired	721408	Direct
2018-05-30	Ordinary Shares	C	275446	—	Acquired	996854	Direct
2018-05-30	Ordinary Shares	C	229660	—	Acquired	1226514	Direct
2018-05-30	Ordinary Shares	P	506656	$13.00	Acquired	1733170	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-30	Series A Preferred Shares	$	C	721408	Disposed		Ordinary Shares (721408)	Direct
2018-05-30	Series B-1 Preferred Shares	$	C	275446	Disposed		Ordinary Shares (275446)	Direct
2018-05-30	Series B-2 Preferred Shares	$	C	229660	Disposed		Ordinary Shares (229660)	Direct

Footnotes

F1: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.

F2: These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Brenton K. Ahrens, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the shares held by the Canaan Fund, except to the extent, if any, of its pecuniary interest therein.

F3: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.

F4: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.